TOP TEN perturbations for 39287_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39287_at
Selected probe(set): 217442_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39287_at (217442_at) across 6674 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 20 (lesional; apremilast; 30mg; baseline) / atopic dermatitis study 20 (lesional; placebo; baseline)

Relative Expression (log2-ratio):1.7186489
Number of Samples:7 / 6
Experimental atopic dermatitis study 20 (lesional; apremilast; 30mg; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before treatment with 30 mg of apremilast (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) and use of biologics within 12 to 24 weeks of baseline.
Control atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):1.4856
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

MALT lymphoma study 1 / normal spleen tissue

Relative Expression (log2-ratio):-1.4628105
Number of Samples:8 / 6
Experimental MALT lymphoma study 1
Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

MALT lymphoma study 2 / normal spleen tissue

Relative Expression (log2-ratio):-1.4403429
Number of Samples:6 / 6
Experimental MALT lymphoma study 2
Human t(11;18)-positive mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3989067
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; placebo; 43d)

Relative Expression (log2-ratio):1.3900247
Number of Samples:8 / 4
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 43d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with placebo.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3811007
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.32656
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3075895
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

psoriasis study 11 (lesional; brodalumab; 43d; 350mg) / psoriasis study 11 (lesional; brodalumab; 8d; 350mg)

Relative Expression (log2-ratio):1.2206097
Number of Samples:4 / 4
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 350mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (350 mg s.c.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; brodalumab; 8d; 350mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 8 (week 1) after treatment with a single dose (350 mg s.c.) of brodalumab. ATC code: